Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.

Lasseter KC, Sologuren A, La Noce A, Dilzer SC.

Clin Drug Investig. 2013 Sep;33(9):665-73. doi: 10.1007/s40261-013-0110-0.

2.

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.

Migoya EM, Stevens CH, Bergman AJ, Luo WL, Lasseter KC, Dilzer SC, Davies MJ, Wagner JA, Herman GA.

Can J Clin Pharmacol. 2009 Winter;16(1):e165-70. Epub 2009 Feb 16.

PMID:
19221403
3.
4.

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.

He YL, Sabo R, Campestrini J, Wang Y, Ligueros-Saylan M, Lasseter KC, Dilzer SC, Howard D, Dole WP.

Eur J Clin Pharmacol. 2007 Jul;63(7):677-86. Epub 2007 May 8.

PMID:
17486328
5.

Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment.

Zimmerman JJ, Lasseter KC, Lim HK, Harper D, Dilzer SC, Parker V, Matschke K.

J Clin Pharmacol. 2005 Dec;45(12):1368-72.

PMID:
16291711
6.

Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.

Turncliff RZ, Dunbar JL, Dong Q, Silverman BL, Ehrich EW, Dilzer SC, Lasseter KC.

J Clin Pharmacol. 2005 Nov;45(11):1259-67.

PMID:
16239359
7.

FTY720 pharmacokinetics in mild to moderate hepatic impairment.

Kovarik JM, Schmouder RL, Serra D, Wang Y, Wiegand H, Dilzer SC, Lasseter KC.

J Clin Pharmacol. 2005 Apr;45(4):446-52.

PMID:
15778425
8.

Potential for interactions between caspofungin and nelfinavir or rifampin.

Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA.

Antimicrob Agents Chemother. 2004 Nov;48(11):4306-14.

9.

Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.

Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC.

Antimicrob Agents Chemother. 2004 Mar;48(3):815-23.

10.

Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.

Lasseter KC, Dilzer SC, Vargas R, Waldman S, Noveck RJ.

Clin Pharmacokinet. 2004;43(2):121-9.

PMID:
14748620
11.

Pharmacokinetics of etoricoxib in patients with hepatic impairment.

Agrawal NG, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, Larson PJ, Cote J, Dilzer SC, Lasseter KC, Alam I, Petty KJ, Gottesdiener KM.

J Clin Pharmacol. 2003 Oct;43(10):1136-48.

PMID:
14517196
12.

Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.

Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, Lasseter K, Rordorf C.

Clin Pharmacol Ther. 2001 Nov;70(5):425-30.

PMID:
11719728
13.

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater DC, Yao SL.

Ann Intern Med. 2000 Jul 4;133(1):1-9.

PMID:
10877734
14.

Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.

Smith DA, Cleary EW, Watkins S, Huffman CS, Dilzer SC, Lasseter KC.

J Clin Pharmacol. 1998 Aug;38(8):685-93.

PMID:
9725543

Supplemental Content

Loading ...
Support Center